Patents Examined by Jeffrey S. Lundgren
  • Patent number: 11324741
    Abstract: Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: May 10, 2022
    Assignee: Nalpropion Pharmaceuticals LLC
    Inventor: Gary D. Tollefson
  • Patent number: 11325913
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: May 10, 2022
    Assignee: THE BROAD INSTITUTE, INC.
    Inventors: Eamon Comer, Nobutaka Kato, Christina Scherer, Jessica Bastien, Jeremy Duvall, Timothy Lewis, Morgane Sayes, Matthew Leighty, Jun Pu, Jennifer Beaudoin, Bertrand Braibant, Benito Munoz
  • Patent number: 11317629
    Abstract: An object of the present invention is to provide a composition which is excellent in plant disease control effect. A liquid composition comprising an effective amount of mefentrifluconazole, 0.1 to 10% by volume of an oil adjuvant, and water.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: May 3, 2022
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Atsushi Watanabe, Yoshinao Sada
  • Patent number: 11318111
    Abstract: Compounds, pharmaceutically acceptable salts, esters, prodrugs, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL5 on mammalian cells, as well as methods of treatment for diseases involving the increased biological activity of CCL5.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: May 3, 2022
    Assignee: LAPKO INC
    Inventor: Bruce Kovacs
  • Patent number: 11318112
    Abstract: A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: May 3, 2022
    Assignee: TASLY PHARMACEUTICAL GROUP CO., LTD.
    Inventors: He Sun, Xijun Yan, Naifeng Wu, Kaijing Yan, Yonghong Zhu, Shunnan Zhang, Xiaolin Bai, Xiaohui Ma, Yi He, Ting Li, Lei Li
  • Patent number: 11298335
    Abstract: Certain embodiments of the invention pertain to a method of treating an infection in a subject caused by an infectious agent other than Escherichia coli, the method comprising administering to the subject arsinothricin or a salt thereof. The infectious agent other than E. coli can be a bacterium, protozoan, helminth, archaebacterium, or a fungus. In preferred embodiments, the infectious agent is Mycobacterium tuberculosis, Mycobacterium bovis, or Enterobacter cloacae. The invention also pertains to a method of treating an infection in a subject caused by an infectious agent, comprising administering to the subject arsinothricin or a salt thereof in combination with an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. In certain such embodiments, the infectious agent expresses phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: April 12, 2022
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Barry Philip Rosen, Masafumi Yoshinaga
  • Patent number: 11298367
    Abstract: The present invention relates to prodrugs of 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[3-(trifluoromethyl)-pyridin-2-yl ]-1H-1,2,4-triazole-5-carboxamide, 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[2-(trifluoromethyl)-phenyl]-1H-1,2,4-triazole-5-carboxamide and 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-(3-chloropyridin-2-yl)-1H-1,2,4-triazole-5-carboxamide, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: April 12, 2022
    Assignee: Bayer Aktiengesellschaft
    Inventors: Marie-Pierre Collin-Kroepelin, Peter Kolkhof, Thomas Neubauer, Chantal Fuerstner, Elisabeth Pook, Matthias Beat Wittwer, Carsten Schmeck, Pierre Wasnaire, Heiko Schirmer, Hana Cernecka, Karoline Droebner, Hanna Tinel, Anja Buchmueller, Thomas Mondritzki, Axel Kretschmer, Klemens Lustig, Robert Fricke, Guillaume Levilain, Ursula Krenz, Norbert Witowski
  • Patent number: 11299491
    Abstract: The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure useful for the synthesis of compounds that target KRAS G12C mutations, such as
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: April 12, 2022
    Assignee: AMGEN INC.
    Inventors: Andrew Thomas Parsons, Brian McNeil Cochran, William Powazinik, IV, Marc Anthony Caporini
  • Patent number: 11298425
    Abstract: A therapeutic method and composition which includes a cannabinoid chemically linked to a chemotherapy agent. The therapeutic composition is capable of crossing the blood-brain barrier, and delivery of the composition across the blood-brain barrier provides both chemotherapy for the treatment of brain cancer and alleviation of side effects caused by the chemotherapy agent. Once across the blood-brain barrier, the chemotherapy agent will be released to attack cancer cells, and the cannabinoid will be free to bind to cannabinoid receptors in the brain to alleviate side effects of chemotherapy such as nausea/vomiting, pain and decreased appetite.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: April 12, 2022
    Assignee: ROWLESBIOMED, LLC
    Inventor: Heidi Rowles
  • Patent number: 11291663
    Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer in a subject having clinical signs of bone marrow homing of myeloid cells, including neutropenia, isolated neutropenia, a low percentage of peripheral blood blasts with or without a high percentage of bone marrow blasts, and/or a low ratio of peripheral blood blasts to bone marrow blasts, with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on hematological characteristics indicating bone marrow homing of myeloid cells.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: April 5, 2022
    Assignee: Kura Oncology, Inc.
    Inventor: Antonio Gualberto
  • Patent number: 11291672
    Abstract: A stable oral spray formulation comprising a glucocorticoid together with other excipients is disclosed. In preferred embodiments, the spray formulation is used to treat neurological disorders such as ataxia by being sprayed in an effective dose into the mouth of a patient.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: April 5, 2022
    Assignee: GRACE THERAPEUTICS INC.
    Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru
  • Patent number: 11285081
    Abstract: In order to enable long-term stabilization of rapamycin contained in a liquid formulation, a formulation sealing vessel of the present invention includes: a sealed vessel body in which a liquid formulation containing 2% (w/w) rapamycin or a salt thereof, 94% (w/w) polyethylene glycol, and 4% (w/w) ethanol is sealed, the sealed vessel body having a volume of 0.1 mL to 1.0 mL, the liquid formulation containing no antioxidant, and the liquid formulation having a total volume of 0.02 mL to 1.0 mL.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: March 29, 2022
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Sreenivasu Mudumba, Kedar Datar, Hiromitsu Shiono, Chun-jung Chu, Le An, Sudeep Rauser
  • Patent number: 11278515
    Abstract: The present invention relates to a pharmaceutical composition or a health functional food composition for improving sleep or preventing or treating sleep disorders comprising beta-lapachone as an active ingredient. Beta-lapachone decreases the sleep latency and increases the total sleeping time, and thus the composition comprising the beta-lapachone can effectively improve sleep and prevent and treat sleep disorders.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: March 22, 2022
    Assignees: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
    Inventors: Yi-Sook Jung, Tae Ho Kim, Se Young Choung
  • Patent number: 11278025
    Abstract: The present application provides compounds and methods of treating bacterial infection, including bacterial infection caused by P. acnes.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: March 22, 2022
    Assignees: The General Hospital Corporation, Rhode Island Hospital, A Lifespan-Partner, Temple University-Of The Commonwealth System of Higher Education
    Inventors: Frederick M. Ausubel, Wooseong Kim, Eleftherios Mylonakis, William M. Wuest
  • Patent number: 11266646
    Abstract: The present application relates to the use of bicyclic-substituted uracil derivatives, alone or in combinations with other active ingredients for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of inflammatory and fibrotic disorders, for the treatment of endometriosis, of endometriosis-associated fibrosis, of adenomyosis and of pain associated with an endometriosis disorder and also of postoperative peritoneal fibrosis and adhesion formation.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: March 8, 2022
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Michaele Peters, Markus Koch, Thomas Zollner
  • Patent number: 11266639
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for treating, inhibiting, or suppressing a hexokinase-2 (HK2)-expressing cancer.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 8, 2022
    Assignee: VIDAC PHARMA LTD.
    Inventors: Vered Behar, Oren Menahem Becker, Hadas Tamar Pahima, Reut Yosef Hamo
  • Patent number: 11267779
    Abstract: The present invention relates to substituted aromatic compounds for use in prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis, where the compound has the following formula: or a pharmaceutically acceptable salt thereof, wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, OH or F; R2 is H, OH, F or CH2—OH; R3 is H, OH, F or CH2Ph; R4 is H, OH or F; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: March 8, 2022
    Assignee: PROMETIC PHARMA SMT LIMITED
    Inventors: Lyne Gagnon, Pierre Laurin, Brigitte Grouix, Lilianne Geerts, François Sarra-Bournet, Martin Leduc
  • Patent number: 11259547
    Abstract: The present invention concerns a composition containing medium-chain fatty acids or salts or mono-, di-, triglycerides, esters or amide derivatives of medium-chain fatty acids. In a further aspect, the present invention concerns also a feed, supplemented with the composition, and a method for feeding animals, in particular calves, cattle and dairy cattle.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: March 1, 2022
    Assignee: Nutrition Sciences N.V.
    Inventors: Geert Bruggeman, Katrien Deschepper
  • Patent number: 11261169
    Abstract: A method for manufacturing an insecticidal compound and insecticidal compositions comprising the insecticidal compound and methods of use are presented herein. The manufacturing method presented herein allows for a high purity grade of thiocyclam hydrochloride to be synthesized. The insecticidal compositions comprising the thiocyclam hydrochloride can be used for prevention of crop destruction by insects. The use of thiocyclam hydrochloride in insecticidal compositions as described herein can achieve greater efficacy than previously known insecticides, by eliminating the insect pests more reliably and efficiently.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: March 1, 2022
    Assignee: ARYSTA LIFESCIENCE NORTH AMERICA, LLC
    Inventors: Cameron S. Gibb, Christopher L. Larson, Mark T. Singleton, Kamal L. Kataria, Samantha Besse, Joseph A. Moore, III, Thomas C. Lovelace, Chandra S. Kanugala, Srinivas Vollala, Balraju Vadla
  • Patent number: 11260051
    Abstract: Stroke patients with comorbidities, such as diabetes, hypertension, or other conditions associated with cardiovascular, pulmonary or renal disease do not respond well to current treatments for stroke. An inhibitor of S-nitrosoglutathione reductase (GSNOR) is administered as an adjunct therapy with remote ischemic conditioning (RIC) to treat a stroke in a subject having at least one comorbidity, such as diabetes and hypertension. When performed in conjunction with GRI therapy and RIC, intravenous tissue plasminogen activator therapy (IVT) for thrombolysis and/or endovascular thrombectomy (EVT) for clot retrieval are effective in subjects with comorbidities, even after five hours post-onset of stroke.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: March 1, 2022
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Syed Kashif Zaidi, Md. Nasrul Hoda, Muhammad Hussain Al-Qahtani